DermTech (OTCPK:DMTK.Q) - Aandelenkoers, Nieuws & Analyse

DMTK.Q Overzicht aandelen

DermTech, Inc., een moleculair diagnostisch bedrijf, houdt zich bezig met de ontwikkeling en marketing van nieuwe niet-invasieve genomicstests voor hulp bij de diagnose en behandeling van melanoom in de Verenigde Staten. Meer informatie

DMTK.Q fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Risicoanalyse

Heeft minder dan 1 jaar cash runway

Heeft geen betekenisvolle marktkapitalisatie ( $35 )

De winst is de afgelopen 5 jaar met 36.7% per jaar gedaald

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

+ 1 meer risico

DermTech, Inc. Concurrenten

Aridis Pharmaceuticals

OTCPK:ARDS

US$53.0

Infinity Pharmaceuticals

OTCPK:INFI.Q

US$90.0

Mymetics

OTCPK:MYMX

US$151.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor DermTech
Historische aandelenkoersen
Huidige aandelenkoers	US$0.000001
52 Week Hoogtepunt	US$1.99
52 Week Laag	US$0.000001
Bèta	2.38
11 maand verandering	-99.00%
3 maanden verandering	-100.00%
1 Jaar Verandering	-100.00%
33 jaar verandering	-100.00%
5 jaar verandering	-100.00%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

May 21

Recent updates

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

May 21

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Mar 02

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Mar 02

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

May 10

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

May 06

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jan 16

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Nov 08

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

Oct 11

DermTech grants stock options

Oct 11

Diving Into DermTech

Sep 01

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

Aug 10

DermTech: Approaching An All Or Nothing Moment

Jun 13

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jun 04

DermTech - Taking A Second Look At The Growth Thesis

Mar 31

DermTech: Adoption Headwinds And Earnings Misses

Dec 23

Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth

Dec 02

Rendement voor aandeelhouders

	DMTK.Q	US Biotechs	US Markt
7D	0%	2.5%	2.2%
1Y	-100.0%	16.1%	31.6%

Rendement versus industrie: DMTK.Q presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 16.1 % opleverde.

Rendement versus markt: DMTK.Q presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.6 % opleverde.

Prijsvolatiliteit

Is DMTK.Q's price volatile compared to industry and market?
DMTK.Q volatility
DMTK.Q Average Weekly Movement	1,039.1%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van DMTK.Q is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van DMTK.Q is het afgelopen jaar gestegen van 523% naar 1039%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	207	n/a	www.dermtech.com

DermTech, Inc., een moleculair diagnostisch bedrijf, houdt zich bezig met de ontwikkeling en marketing van nieuwe niet-invasieve genomics-tests om te helpen bij de diagnose en het beheer van melanoom in de Verenigde Staten. Het bedrijf biedt de DermTech Melanoma Test (DMT), een innovatieve niet-invasieve manier om melanoomdetectie te verbeteren voor het ontwikkelen van een product voor niet-melanoom huidkanker. Het biedt ook DermTech Smart Sticker, die een niet-invasieve manier biedt om huidmonsters te verzamelen, inclusief standaardzorg door het gebruik van een scalpel om verdachte laesies te biopteren.

DermTech, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van DermTech zich tot de beurswaarde?
DMTK.Q fundamentele statistieken
Marktkapitalisatie	US$35.00
Inkomsten(TTM)	-US$89.63m
Inkomsten(TTM)	US$15.66m

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is DMTK.Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
DMTK.Q resultatenrekening (TTM)
Inkomsten	US$15.66m
Kosten van inkomsten	US$14.33m
Brutowinst	US$1.33m
Overige uitgaven	US$90.96m
Inkomsten	-US$89.63m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.54
Brutomarge	8.51%
Nettowinstmarge	-572.19%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde DMTK.Q op de lange termijn?

Bekijk historische prestaties en vergelijking

DMTK.Q Overzicht aandelen

Risicoanalyse

DermTech, Inc. Concurrenten

OTCPK:ARDS

US$53.0

OTCPK:INFI.Q

US$90.0

OTCPK:MYMX

US$151.0

OTCPK:PLXP.Q

US$30.0

Prijsgeschiedenis en prestaties

Recent nieuws en updates

DermTech, Inc.(NasdaqCM:DMTK) dropped from NASDAQ Composite Index

Nasdaq to Delist Common Stock of DermTech

Motion for Joint Administration Filed by DermTech, Inc.

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

Kilroy Realty, L.P. Files a Complaint Against DermTech, Inc. for $661,706 in Unpaid Rent

First quarter 2024 earnings released: US$0.58 loss per share (vs US$1.02 loss in 1Q 2023)

Recent updates

DermTech, Inc.(NasdaqCM:DMTK) dropped from NASDAQ Composite Index

Nasdaq to Delist Common Stock of DermTech

Motion for Joint Administration Filed by DermTech, Inc.

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

Kilroy Realty, L.P. Files a Complaint Against DermTech, Inc. for $661,706 in Unpaid Rent

First quarter 2024 earnings released: US$0.58 loss per share (vs US$1.02 loss in 1Q 2023)

Price target decreased by 26% to US$2.04

DermTech Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Minimum Bid Price Requirement

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 11% to US$3.20

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

DermTech, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer

DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test (Dmt) Across All Skin Types

DermTech, Inc. Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-On Assay

Dermtech Announces Positive Topline Results from Trust 2 Study Evaluating the Dermtech Melanoma Test (Dmt)

Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price

Pomerantz LLP Announces the Filing of A Class Action Against DermTech, Inc. and Certain Officers

Consensus EPS estimates upgraded to US$3.11 loss

Third quarter 2023 earnings: EPS exceeds analyst expectations

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against DermTech, Inc

DermTech, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Dermtech Appoints Mark Aguillard as Chief Commercial Officer

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

DermTech, Inc. to Report Q2, 2023 Results on Aug 03, 2023

DermTech, Inc. Announces the Todd Wood’s Last Day of Employment as Chief Commercial Officer Will Be July 3, 2023

DermTech, Inc. Announces ECRI Complete Its Evaluation of the Pigmented Lesion Assay

Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Consensus revenue estimates fall by 16%

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

DermTech, Inc. Announces Change of CEO

Price target decreased by 22% to US$5.75

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

First quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 11% to US$7.00

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

DermTech, Inc. to Report Q4, 2022 Results on Mar 02, 2023

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

DermTech, Inc. Announces the Foundational Assay of Its DermTech Melanoma Test Is Recommended for Coverage by TRICARE

DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its Dermtech Melanoma Test (Dmt)

Price target decreased to US$7.33

High number of new directors

DermTech, Inc. Announces Board Committee Appointments

Consensus forecasts updated

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

DermTech, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

DermTech grants stock options

Diving Into DermTech

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

Dermtech, Inc. Provides Revenue Guidance for the Full Year 2022

DermTech, Inc. Appoints Chief Compliance Officer and SVP of Research and Development

DermTech, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Dermtech Announces New Board Appointment